A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

HomeTagsVeracyte

Veracyte

Data Presented at ASTRO 2021 Validate Prognostic Value of Decipher Prostate Genomic Test in Newly Diagnosed, Clinically High-Risk Prostate Cancer

“This analysis provides the first clinical evidence that the Decipher Prostate classifier can help physicians and patients make critical, personalized treatment decisions in the post-biopsy, clinically high-risk prostate cancer setting,” said Elai Davicioni, Ph.D., Veracyte’s senior vice president of scientific and clinical operations, Urologic Cancers.

Veracyte and MAVIDx Agreement in Place

Veracyte and MAVIDx agreement is intended to enable diagnostic testing and population screening for COVID-19 at an unprecedented scale – up to 40,000 samples per day performed on the easy-to-use nCounter instrument – through technology that attaches molecular barcodes to individual RNA molecules of the virus. 
Spot_ImgSpot_Img

By using this website you agree to accept Medical Device News Magazine Privacy Policy